INVA - Innoviva, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.34
|
Rev Est: $102.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.67
DETAILS
HIGH:
$46.00
LOW:
$17.00
MEDIAN:
$35.00
CONSENSUS:
$32.67
UPSIDE:
39.50%
Market Cap:
1.51B
Volume:
831,648
Avg Volume:
816,118
52 Week Range:
16.52-24.01
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.45
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
127
IPO Date:
2004-10-05
EPS (TTM):
0.37
P/E Ratio:
46.52
Revenue (TTM):
358.71M
Total Assets:
1.30B
Total Debt:
451.10M
Cash & Equiv:
304.96M
Rev Growth (5Y):
6.6%
EPS Growth (5Y):
-25.0%
FCF Growth (5Y):
-6.0%
ROCE:
5.6%
Debt/Equity:
0.65
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $1.08 | $0.46 | +134.8% | $107.8M | $101.5M | +6.2% |
| 2025-08-06 | $0.77 | $0.57 | +35.1% | $100.3M | $90.9M | +10.3% |
| 2025-05-07 | $0.25 | $0.29 | -13.8% | $88.6M | $82.7M | +7.2% |
| 2025-02-26 | $0.57 | $0.34 | +67.6% | $91.8M | $92.6M | -0.8% |
| 2024-11-06 | $0.02 | $0.27 | -92.6% | $89.5M | $88.2M | +1.5% |
| 2024-07-31 | $0.68 | $0.24 | +183.3% | $103.4M | $74.7M | +38.4% |
| 2024-05-08 | $0.46 | $0.17 | +170.6% | $81.0M | $68.0M | +19.1% |
| 2024-02-29 | $0.76 | $0.23 | +230.4% | $89.3M | $75.5M | +18.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 358.71M | 310.46M | 331.34M | 391.87M | 336.79M | 261.02M | 261.00M | 217.22M | 133.57M | 53.95M | 8.43M | 4.76M |
| Net Income | 23.39M | 179.72M | 213.92M | 265.85M | 224.40M | 157.29M | 395.06M | 134.14M | 59.54M | (18.76M) | (168.46M) | (170.70M) |
| EPS | 0.37 | 2.92 | 3.07 | 3.24 | 2.21 | 1.56 | 3.53 | 1.25 | 0.54 | -0.16 | -1.51 | -1.67 |
| Total Assets | 1.30B | 1.24B | 1.23B | 926.39M | 999.57M | 724.83M | 548.19M | 367.34M | 379.00M | 424.07M | 521.65M | 681.25M |
| Total Debt | 451.10M | 449.08M | 544.07M | 394.76M | 385.52M | 377.12M | 382.86M | 599.36M | 716.09M | 748.27M | 725.64M | 287.50M |
| Cash & Equivalents | 304.96M | 193.51M | 291.05M | 201.53M | 246.49M | 278.10M | 62.42M | 73.34M | 118.02M | 159.18M | 96.80M | 143.51M |
| Operating Cash Flow | 188.69M | 141.06M | 201.73M | 363.81M | 313.11M | 257.46M | 223.53M | 141.75M | 60.98M | 10.13M | (130.72M) | (129.60M) |
| Free Cash Flow | 188.42M | 140.65M | 201.66M | 362.51M | 313.10M | 257.45M | 223.53M | 141.75M | 60.71M | 10.12M | (131.41M) | (217.34M) |
| FCF per Share | 3.00 | 2.15 | 2.90 | 4.42 | 3.09 | 2.55 | 2.22 | 1.33 | 0.55 | 0.09 | -1.17 | -2.12 |
| Book Value | 691.16M | 674.96M | 565.79M | 414.74M | 539.91M | 313.50M | 153.58M | (242.86M) | (352.99M) | (342.64M) | (223.35M) | 299.12M |
| Cash & ST Investments | 412.50M | 193.51M | 291.05M | 201.53M | 246.49M | 350.85M | 114.91M | 129.07M | 150.43M | 187.28M | 240.50M | 465.12M |
| ROC Equity | 0.03 | 0.27 | 0.38 | 0.64 | 0.42 | 0.50 | 2.57 | N/A | N/A | N/A | N/A | -0.57 |